Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Journal of Surgical Oncology

Volumn 100, Issue 4, 2009, Pages 317-320

  Piso, Pompiliu ^a   Glockzin, Gabriel ^a   Von Breitenbuch, Phillipp ^a   Popp, Felix Cristoph ^a   Dahlke, Marc Hendrik ^a   Schlitt, Hans J ^a   Nissan, Aviram ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Long term results; Morbidity; Peritonectomy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ANASTOMOSIS LEAKAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; INTESTINE OBSTRUCTION; LIFE EXPECTANCY; LUNG EMBOLISM; PERITONEUM CANCER; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SURGICAL INFECTION; THROMBOSIS;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; PERITONEAL NEOPLASMS; QUALITY OF LIFE;

EID: 69749086478     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21327     Document Type: Conference Paper

References (36)

1. Nazareno J, Taves D, Preiksaitis HG: Metastatic breast cancer to the gastrointestinal tract: A case series and review of the literature. World J Gastroenterol 2006;12:6219-6224. (Pubitemid 44688177)
2. Neumann V, Muller KM, Fischer M: Peritoneal mesothelioma-incidence and etiology. Pathologe 1999;20:169-176.
3. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-3639. (Pubitemid 30051820)
4. Van Cutsem E, Geboes K: The muslidisciplinary management of gastrointestinal cancer. The intergration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Clin Gastroenterol 2007;21:1089-1108.
5. Glockzin G, Ghali N, Lang SA, et al.: Peritoneal carcinomatosis. Surgical treatment, including hyperthermic intraperitoneal chemotherapy. Chirurg 2007;78:1102-1106.
6. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
7. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83-97. (Pubitemid 19215266)
8. Koller M, Lorenz W: Quality of life: A deconstruction for clinicians. J R Soc Med 2002;95:481-488.
9. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.
10. Di Giorgio A, Naticchioni E, Biacchi D, et al.: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113:315-325.
11. Yan TD, Edwards G, Alderman R, et al.: Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma - A prospective study of 70 consecutive cases. Ann Surg Oncol 2007;14:515-525. (Pubitemid 46175296)
12. Hirose K, Katayama K, Iida A, et al.: Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: Evaluation by multivariate regression analysis. Oncology 1999;57:106-114. (Pubitemid 29385487)
13. Glehen O, Schreiber V, Cotte E, et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-26. (Pubitemid 38049613)
14. Yonemura Y, Kawamura T, Bandou E, et al.: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370-375. (Pubitemid 40445602)
15. Cheong JH, Shen JY, Song CS, et al.: Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol 2007;14:61-68.
16. Culliford AT, Brooks AD, Sharma S, et al.: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787-795. (Pubitemid 34003327)
17. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284-3292. (Pubitemid 41103684)
18. Shen P, Hawksworth J, Lovato J, et al.: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178-186. (Pubitemid 40486793)
19. Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.
20. Elias D, Delperro JR, Sideris L, et al.: Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518-521. (Pubitemid 40486734)
21. Mahteme H, Hansson J, Berglund A, et al.: Improved survival in patients with peritoneal metastases from colorectal cancer: A preliminary study. Br J Cancer 2004;90:403-407. (Pubitemid 38250636)
22. Yan TD, Welch L, Black D, et al.: A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827-834. (Pubitemid 47054078)
23. Schmidt U, Dahlke MH, Klempnauer J, et al.: Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:53-58. (Pubitemid 40103925)
24. McQuellon RP, Loggie BW, Fleming RA, et al.: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65-73.
25. McQuellon RP, Loggie BW, Lehman AB, et al.: Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155-162. (Pubitemid 40485936)
26. McQuellon RP, Danhauer SC, Russell GB, et al.: Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2006;14:1105-1113.
27. McQuellon RP, Russell GB, Shen P, et al.: Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol 2007;15:125-133.
28. McQuellon R, Gavazzi C, Piso P, et al.: Quality of life and nutritional assessment in peritoneal surface malignancy: Recommendations for care. J Surg Oncol 2008;98:300-305.
29. Alexander R, Mavroukakis S, Libutti S, et al.: Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. Proc Soc Surg Oncol 2005; S109.
30. Tuttle TM, Zhang Y, Greeno E, et al.: Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2006;13:1627-1632. (Pubitemid 44951472)
31. Eton D, Fairclough D, Cella D, et al.: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003;21:1536-1543. (Pubitemid 46594107)
32. Ware JE, Snow KK, Kosinski M, et al.: SF-36 health survey. In: Manual and interpretation guide. Boston: Nimrod Press; 1993.
33. Radloff LS: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
34. Zubrod CG, Schneidermann M, Frei E: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33.
35. McQuellon RP, Russell GB, Rambo TD: Quality of life and psychological distress of bone marrow transplant recipients: The time trajectory to recovery over the first year. Bone Marow Transplant 1998;21:477-486.
36. Yoo HJ, Kim JC, Eremenco S, et al.: Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy - Colorectal (FACT-C), Version 4. J Pain Symptom Manage 2005;30:24-32. (Pubitemid 41021676)